dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Griguolo, Gaia |
dc.contributor.author | Pascual, Tomás |
dc.contributor.author | Fasani, Roberta |
dc.contributor.author | Chic, N. |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Nuciforo, Paolo Giovanni |
dc.contributor.author | Serna, Garazi |
dc.contributor.author | Guardia, Xavier |
dc.date.accessioned | 2021-11-15T11:51:12Z |
dc.date.available | 2021-11-15T11:51:12Z |
dc.date.issued | 2021-03-19 |
dc.identifier.citation | Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, et al. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021 Mar 19;5(1):23. |
dc.identifier.issn | 2397-768X |
dc.identifier.uri | https://hdl.handle.net/11351/6546 |
dc.description | Dried plasma spot; Hepatitis C; Plasma separation card |
dc.description.abstract | Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes in tumour-immune contexture, as assessed by stromal tumour-infiltrating lymphocytes (sTILs) and by multiplexed spatial cellular phenotyping, during treatment with lapatinib-trastuzumab in HER2+ BC patients (PAMELA trial). Moreover, we evaluate the relationship of tumour-immune contexture with hormone receptor status, intrinsic subtype and immune-related gene expression. sTIL levels increase after 2 weeks of HER2 blockade in HR-negative disease and HER2-enriched subtype. This is linked to a concomitant increase in cell density of all four immune subpopulations (CD3+, CD4+, CD8+, Foxp3+). Moreover, immune contexture analysis showed that immune cells spatially interacting with tumour cells have the strongest association with response to anti-HER2 treatment. Subsequently, sTILs consistently decrease at the surgery in patients achieving pathologic complete response, whereas most residual tumours at surgery remain inflamed, possibly reflecting a progressive loss of function of T cells. Understanding the features of the resulting tumour immunosuppressive microenvironment has crucial implications for the design of new strategies to de-escalate or escalate systemic therapy in early-stage HER2+ BC. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | NPJ Precision Oncology;5(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /therapy |
dc.subject.mesh | Neoadjuvant Therapy |
dc.title | Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41698-021-00163-6 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /terapia |
dc.subject.decs | tratamiento neoadyuvante |
dc.relation.publishversion | https://doi.org/10.1038/s41698-021-00163-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Griguolo G] Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Serna G, Fasani R, Guardia X] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pascual T] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Chic N] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain |
dc.identifier.pmid | 33742063 |
dc.identifier.wos | 000631563100004 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00904 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |